Ibogaine is a psychoactive substance that a growing body of research shows can help treat opioid use disorder, traumatic brain injury, depression, and post-traumatic stress disorder by physically repairing damaged brain tissue. This model legislation is intended to authorize state ibogaine research and authorize participation in a larger multistate effort to complete a Food and Drug Administration (FDA) supervised clinical drug trial.
The trial would seek approval of ibogaine as a treatment for opioid use disorder, depression, post-traumatic stress disorder, and other behavioral health conditions, especially those suffered by military veterans. If the FDA approves ibogaine to treat a medical condition, the legislation would allow licensed physicians to prescribe ibogaine administration for a patient under supervision.